Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 May;36(5):1133–1135. doi: 10.1128/aac.36.5.1133

Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents.

V G Loo 1, P Sherman 1, A G Matlow 1
PMCID: PMC188850  PMID: 1510406

Abstract

The in vitro activities of omeprazole and eight antimicrobial agents against 18 clinical strains of Helicobacter pylori isolated from a pediatric population were determined by an agar dilution method. Ampicillin and erythromycin were the most active agents in vitro. All strains were susceptible to azithromycin, ciprofloxacin, doxycycline, metronidazole, and tinidazole. One isolate demonstrated resistance to cefixime (MIC, greater than or equal to 4 micrograms/ml). H. pylori was inhibited by the proton pump inhibitor omeprazole.

Full text

PDF
1133

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Fuchs P. C. In-vitro potency of azithromycin against gram-negative bacilli is method-dependent. J Antimicrob Chemother. 1991 Oct;28(4):607–610. doi: 10.1093/jac/28.4.607. [DOI] [PubMed] [Google Scholar]
  2. Barry A. L., Jones R. N. Interpretative criteria for the agar diffusion susceptibility test with azithromycin. J Antimicrob Chemother. 1988 Nov;22(5):637–641. doi: 10.1093/jac/22.5.637. [DOI] [PubMed] [Google Scholar]
  3. Biasco G., Miglioli M., Barbara L., Corinaldesi R., di Febo G. Omeprazole, Helicobacter pylori, gastritis, and duodenal ulcer. Lancet. 1989 Dec 9;2(8676):1403–1403. doi: 10.1016/s0140-6736(89)92021-7. [DOI] [PubMed] [Google Scholar]
  4. Blaser M. J. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis. 1990 Apr;161(4):626–633. doi: 10.1093/infdis/161.4.626. [DOI] [PubMed] [Google Scholar]
  5. Czinn S. J., Speck W. T. Campylobacter pylori: a new pathogen. Adv Pediatr Infect Dis. 1990;5:221–237. [PubMed] [Google Scholar]
  6. Drumm B., O'Brien A., Cutz E., Sherman P. Campylobacter pyloridis-associated primary gastritis in children. Pediatrics. 1987 Aug;80(2):192–195. [PubMed] [Google Scholar]
  7. Drumm B., Perez-Perez G. I., Blaser M. J., Sherman P. M. Intrafamilial clustering of Helicobacter pylori infection. N Engl J Med. 1990 Feb 8;322(6):359–363. doi: 10.1056/NEJM199002083220603. [DOI] [PubMed] [Google Scholar]
  8. Drumm B., Sherman P., Cutz E., Karmali M. Association of Campylobacter pylori on the gastric mucosa with antral gastritis in children. N Engl J Med. 1987 Jun 18;316(25):1557–1561. doi: 10.1056/NEJM198706183162501. [DOI] [PubMed] [Google Scholar]
  9. Drumm B., Sherman P. Long-term storage of Campylobacter pylori. J Clin Microbiol. 1989 Jul;27(7):1655–1656. doi: 10.1128/jcm.27.7.1655-1656.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fiese E. F., Steffen S. H. Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):39–47. doi: 10.1093/jac/25.suppl_a.39. [DOI] [PubMed] [Google Scholar]
  11. Foulds G., Shepard R. M., Johnson R. B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):73–82. doi: 10.1093/jac/25.suppl_a.73. [DOI] [PubMed] [Google Scholar]
  12. Ghelani A. M., Hale S., Coleman H., Radziwonik H., Robertson C., Atkinson M. Lack of in vitro activity of omeprazole against Campylobacter pylori. J Clin Pathol. 1990 Feb;43(2):171–172. doi: 10.1136/jcp.43.2.171-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Glupczynski Y., Burette A. Failure of azythromycin to eradicate Campylobacter pylori from the stomach because of acquired resistance during treatment. Am J Gastroenterol. 1990 Jan;85(1):98–99. [PubMed] [Google Scholar]
  14. Glupczynski Y., Delmee M., Bruck C., Labbe M., Avesani V., Burette A. Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents. Eur J Epidemiol. 1988 Jun;4(2):154–157. doi: 10.1007/BF00144743. [DOI] [PubMed] [Google Scholar]
  15. Mainguet P., Delmée M., Debongnie J. C. Omeprazole, campylobacter pylori, and duodenal ulcer. Lancet. 1989 Aug 12;2(8659):389–390. doi: 10.1016/s0140-6736(89)90569-2. [DOI] [PubMed] [Google Scholar]
  16. Marshall B. J., Armstrong J. A., McGechie D. B., Glancy R. J. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust. 1985 Apr 15;142(8):436–439. doi: 10.5694/j.1326-5377.1985.tb113443.x. [DOI] [PubMed] [Google Scholar]
  17. Marshall B. J., McGechie D. B., Rogers P. A., Glancy R. J. Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust. 1985 Apr 15;142(8):439–444. doi: 10.5694/j.1326-5377.1985.tb113444.x. [DOI] [PubMed] [Google Scholar]
  18. Maton P. N. Omeprazole. N Engl J Med. 1991 Apr 4;324(14):965–975. doi: 10.1056/NEJM199104043241406. [DOI] [PubMed] [Google Scholar]
  19. McNulty C. A., Dent J., Wise R. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother. 1985 Dec;28(6):837–838. doi: 10.1128/aac.28.6.837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Morris A., Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol. 1987 Mar;82(3):192–199. [PubMed] [Google Scholar]
  21. Nomura A., Stemmermann G. N., Chyou P. H., Kato I., Perez-Perez G. I., Blaser M. J. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991 Oct 17;325(16):1132–1136. doi: 10.1056/NEJM199110173251604. [DOI] [PubMed] [Google Scholar]
  22. Parsonnet J., Friedman G. D., Vandersteen D. P., Chang Y., Vogelman J. H., Orentreich N., Sibley R. K. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991 Oct 17;325(16):1127–1131. doi: 10.1056/NEJM199110173251603. [DOI] [PubMed] [Google Scholar]
  23. Rauws E. A., Langenberg W., Houthoff H. J., Zanen H. C., Tytgat G. N. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology. 1988 Jan;94(1):33–40. [PubMed] [Google Scholar]
  24. Tatsuta M., Ishikawa H., Iishi H., Okuda S., Yokota Y. Reduction of gastric ulcer recurrence after suppression of Helicobacter pylori by cefixime. Gut. 1990 Sep;31(9):973–976. doi: 10.1136/gut.31.9.973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Westblom T. U., Gudipati S., Midkiff B. R. In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime. Eur J Clin Microbiol Infect Dis. 1990 Sep;9(9):691–693. doi: 10.1007/BF01964274. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES